Early Versus Delayed Rehabilitation After Reverse Total Shoulder Arthroplasty for Proximal Humerus Fracture
Launched by UNIVERSITY OF VIRGINIA · Mar 7, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best timing for rehabilitation after a special type of shoulder surgery called reverse total shoulder arthroplasty (rTSA), which is often needed after a serious shoulder fracture in older adults. The goal is to find out whether starting rehabilitation early after the surgery can help patients recover better and experience fewer complications compared to delaying rehabilitation. This is important because patients with these types of fractures often have more challenges in their recovery, and there's currently no clear guideline on how to manage rehabilitation after surgery.
To participate in this trial, individuals need to be between the ages of 50 and 85 and must be scheduled to undergo rTSA for a proximal humerus fracture by a single surgeon. Those who have had previous shoulder surgeries on the same side, are having elective surgery, or are unable to attend follow-up visits will not be eligible. Participants can expect to be randomly assigned to either start rehabilitation right after surgery or to begin it later. Throughout the study, researchers will carefully monitor their recovery to see which approach leads to better outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 50-85 undergo reverse Total Shoulder Arthroplasty by a single surgeon for proximal humerus fractures
- Exclusion Criteria:
- • previous rTSA to ipsilateral shoulder
- • undergoing elective rTSA
- • Prisoners
- • unwilling to be randomized
- • unwilling or unable to attend follow up visits
About University Of Virginia
The University of Virginia (UVA) is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on interdisciplinary collaboration, UVA leverages its extensive resources and expertise in various fields, including medicine, engineering, and public health, to drive cutting-edge studies that address pressing health challenges. The university's clinical trial programs aim to translate scientific discoveries into effective treatments, ensuring the highest standards of ethical practice and participant safety. Through its strong emphasis on community engagement and education, UVA fosters a culture of research that not only contributes to the scientific community but also enhances the well-being of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlottesville, Virginia, United States
Patients applied
Trial Officials
Seth Yarboro, MD
Principal Investigator
University of Virginia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported